Skip to content
Clinical Trials – home
AustriaBack to Austria

Clinical trials in Rankweil

7 clinical trials in Rankweil, Austria. Every trial is listed in the EU Clinical Trials Register and updated daily.

Rankweil at a glance
7
clinical trials
  • Not yet recruiting0
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

7 trials in Rankweil

Open in trial search
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Pfizer Inc.
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:Universitaetsklinikum Ulm AöR
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB
Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Other cities in Austria

The busiest research cities in the country

All 47 cities in Austria

Clinical research in Rankweil

What the registry says about research in the country

01 Lung Cancer Research

Groundbreaking studies focusing on both small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), evaluating innovative combination therapies and treatment approaches.

  • Extensive-Stage SCLC Treatment
  • Early-Stage NSCLC Management
  • Advanced NSCLC Therapies

Multiple trials exploring immunotherapy combinations with chemotherapy for improved patient outcomes.

02 Surgical Oncology

Research investigating perioperative treatment strategies for resectable lung cancer, combining innovative immunotherapy approaches with standard surgical interventions.

  • Pre-surgical Immunotherapy
  • Post-operative Treatment
  • Combined Modality Approaches

Studies aim to enhance surgical outcomes and prevent disease recurrence in operable cases.

03 Hematologic Oncology

Innovative research in multiple myeloma treatment, evaluating novel therapeutic combinations for transplant-ineligible patients with newly diagnosed disease.

  • Novel Drug Combinations
  • First-line Therapies
  • Treatment Optimization

Focus on improving treatment responses and patient outcomes in blood cancer management.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.